NCT00291343 - Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study | Biotech Hunter

Enrollment

296

Participants

Timeline

Start Date

February 1, 2006

Primary Completion Date

March 15, 2007

Study Completion Date

March 15, 2007

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Tritanrix™- HepB

One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months

BIOLOGICAL

Hiberix™

One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months

BIOLOGICAL

Mencevax™ ACWY

One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months

Trial Locations (2)

GSK Investigational Site, Manila

GSK Investigational Site, Sampaloc, Manila